



## Cancer Immunotherapy: Current Advancements and Future Perspectives

Guest Editors:

**Dr. Stefano Forte**

Istituto Oncologico del  
Mediterraneo, 95029 Viagrande,  
Italy

**Dr. Gianluca Ferini**

REM Radioterapia, 95029  
Viagrande, Italy

Deadline for manuscript  
submissions:

**20 January 2025**

### Message from the Guest Editors

Dear Colleagues,

The goal of immune therapy is to elicit and maintain an immune mediation response to cancer cells to establish a self-sustained process. This approach demonstrates its significant effectiveness in diseases where therapeutic options are not particularly effective. Unfortunately, the percentage of patients who benefit from these treatments remains limited. Regarding radiotherapy, it is well-known that it can induce abscopal and bystander effects by recruiting immune cells against the tumor. Unfortunately, such responses are episodic and not systematically inducible. These may be synergized and promoted by immunotherapy. Bench-to-bedside and vice versa findings are welcome in this Special Issue to shed light on the rationale and mechanisms of these new therapeutic opportunities.

The weapon of immunotherapy should be made effective for a larger number of patients. It is also important to effectively combine immunotherapy with chemotherapy, radiotherapy or targeted therapies aiming towards a complete and sustainable disease eradication.

Dr. Stefano Forte

Dr. Gianluca Ferini

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer  
Institute, Winston-Salem, NC  
27103, USA  
2. Division of Hematologic  
Malignancies and Cellular  
Therapy, Duke University,  
Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM; ISSN 2075-4426)* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

---

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[X@JPM\\_MDPI](https://twitter.com/JPM_MDPI)